Member Login
Search

What’s New at GRAPPA

The GRAPPA app has launched!

The GRAPPA app, available in Apple and Android formats, is free to download from the Apple store and the Google Play Store.  Designed to be used by physicians, this app includes calculators for outcome measures including treat to target with the MDA criteria, the PASI and body surface area.  It also has the psoriasis epidemiology screening tool (PEST) questionnaire to screen for PsA in patients with psoriasis and the PsA impact of disease (PsAID) calculator to measure both PsAID 9 and PsAID 12.  Until mid-2018 the app is only available in English, but in the following months it will also launch in French, German, Italian, Spanish, Portuguese (for both Portugal and Brazil), Traditional Chinese, Simplified Chinese, Russian, Arabic, Japanese and Hebrew. Please check back for updates on these additional language versions.

We are very grateful for grant support from AbbVie, Eli Lilly, Novartis and Pfizer which allowed GRAPPA to complete this work.

The app is free to download to all, both GRAPPA members and non-members. Here are the links:

                                    
                                                                           Google Play and the Google Play logo are trademarks of Google LLC.

GRAPPA Mission

GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) is organized exclusively for non-profit, educational, and scientific purposes, specifically to facilitate sharing of information related to psoriasis and psoriatic arthritis, networking among different medical disciplines that see psoriasis and psoriatic arthritis patients, and to enhance research, diagnosis and treatment of psoriasis and psoriatic arthritis.

2018 GRAPPA Pilot Research Grants awardees named
Young researchers for three promising pilot studies are being awarded $25,000 to pursue their work.
Fardina Malik, MD of New York University Medical Center (USA) will pursue research on Gut Microbiota as Predictor and Modulator of Methotrexate Response in Early Psoriatic Arthritis.
Kim Wervers and Hannah den Braanker were also awarded $25,000. Their work at Maasstad Hospital and Erasmus MC in the Netherlands focuses on Response to Methotrexate and a Quest for Personalized Medicine in Psoriatic Arthritis.
Graham A. Chapman of the University of Leeds (UK) submitted the third winning proposal, Is Toe Dactylitis in Psoriatic Arthritis Related to Trauma Caused by Plantar Shear Stress? A Case Control Pilot Study.
“Although we received twenty proposals this year, and it was very competitive, these three rose to top,” said Christopher Ritchlin, MD, co-chair of the GRAPPA Research Committee.  “We look forward to seeing what their novel work reveals.”